Inflammatory phenotyping predicts clinical outcome in COVID-19

Area of Science:

• Immunology
• Infectious Diseases
• Critical Care Medicine

Background:

• COVID-19 has caused significant global mortality, with hyperinflammation implicated in severe disease.
• Identifying hyperinflammatory COVID-19 patients may enable targeted immunomodulatory treatments.
• Cytokine profiling at diagnosis can predict patient deterioration risk.

Purpose of the Study:

• To assess the predictive value of cytokine levels for adverse outcomes in hospitalized COVID-19 patients.
• To determine if a combined cytokine panel improves outcome prediction compared to clinical data alone.

Main Methods:

• Serum samples from 100 hospitalized COVID-19 patients were analyzed using a multiplex cytokine assay.
• Key cytokines measured included IL-6, IL-8, TNF, IL-1β, GM-CSF, IL-10, IL-33, and IFN-γ.
• Demographic, clinical, and outcome data were collected and analyzed.

Main Results:

• Age >70 years was the strongest predictor of death.
• Elevated IL-6, IL-8, TNF, IL-1β, and IL-33 levels were associated with adverse outcomes.
• A combined cytokine panel significantly improved prediction of adverse outcomes (AUROC 0.85) compared to clinical parameters alone (AUROC 0.71).

Conclusions:

• A combined cytokine panel enhances the prediction of adverse outcomes in COVID-19 patients beyond standard clinical data.
• Specific cytokine identification aids in stratifying patients for immunomodulatory treatment trials.
• This approach may improve treatment strategies and patient outcomes in COVID-19.